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Accepted 8 August 2013AbstractMicroRNAs (miRNAs, miRs) are a cluster of naturally occurring small non-coding RNA molecules of 19e24 nucleotides in length. miRs
control gene expression post-transcriptionally by binding to a specific site at the 30-UTR of target mRNA, which results in mRNA cleavage and
translation repression. Nearly 1000 miRs in the human genome have been identified, and it is believed that these miRs contribute to at least 60%
of the human transcriptome. Recent research has shown that miRs are emerging as important regulators of cellular differentiation and dedif-
ferentiation. In addition, dysregulation of miR expression may play a fundamental role in the onset, progression and dissemination of cancers. In
this review, we focus on some paradigms of miR involvement in tumorigenesis, such as ovarian cancer, and also discuss the relationship between
miRs and cancer stem cells.
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MicroRNAs (miRNAs, miRs) are a cluster of naturally
occurring small non-coding RNA molecules of 19e24 nu-
cleotides in length (single-stranded RNAs, ssRNAs), that post-
transcriptionally control gene expression by binding to a
specific site at the 30-untranslated region (30-UTR) of target
mRNA, inducing mRNA cleavage and translation repression
[1]. miR biogenesis involves the maturation of miR precursors,
assembly of the mature miR into microprocessor complexes
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http://dx.doi.org/10.1016/j.tjog.2013.10.002by degrading and/or blocking translation of mRNA targets [2].
Bioinformatic analyses have predicted the existence of nearly
1000 miRs in the human genome [3]. miRs are involved in
virtually all biological processes, including gene regulation,
cell developmental control, for example, cell proliferation,
differentiation and apoptosis, and stemness. In addition,
because gene expression mediated by miRs is accomplished by
imperfect base pairing together with protein translational
repression of the target gene, and the specificity of miR tar-
geting is mediated by only six to 11 nucleotides, a single miR
can target hundreds of mRNAs [2], aberrant miR expression
may be involved in the initiation of various types of diseases,
including cancer [4,5]. Furthermore, because dysregulation of
miR expression may play a fundamental role in the onset,
progression, and dissemination of cancer, measuring circu-
lating miR levels may be useful in early cancer detection,
which can significantly contribute to treatment success.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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via recent biotechnology might provide a potential therapeutic
role [2]. In this review, we focus on some paradigms of miR
involvement in tumorigenesis, for example, ovarian cancer,
and we also discuss the relationship between miRs and cancer
stem cells (CSCs).
Altered miRs are always found in all cancers
Growing evidence has demonstrated that miRs can act as
either oncogenes or tumor-suppressor genes [2]. However, the
categorization of miRs as oncogenes or tumor-suppressor
genes based on their levels of expression in tumors versus
normal tissues has proven to be inaccurate, because experi-
ments have shown that many function dually as both onco-
genes and tumor-suppressor genes depending on the cancer
type, stage and cellular context [2]. Regarding the relationship
between miRNAs and cancer, B cell chronic lymphocytic
leukemia might be the first human malignancy known to be
associated with miR dysregulation [miR-15 and miR-16 are
deleted or downregulated in the majority (68%) of patients
with chronic lymphocytic leukemia] [5,6]. With regard to solid
tumors, colon cancer might be one of the first studies of miRs
in solid tumors, where, in a study, 28 miRs differentially
expressed between colonic cancer and normal mucosa were
identified, and it was concluded that levels of miR-143a and
miR-145a were significantly lower in tumors than in normal
tissue [7]. Later, genome-wide miR expression profiling
studies using high-throughput technologies demonstrated that
almost all cancer types present a specific profile of upregulated
and downregulated miRs [2,8]. Among these miRs, more and
more evidence has supported the prominent role of miR-21.
miR-21 is upregulated in various solid tumors, such as glio-
blastoma and astrocytoma, as well as hematological malig-
nancies [2,9], and overexpression of miR-21 has been shown to
promote cancer cell proliferation and migration, and affect
survival of patients; therefore, miR-21 can be considered an
oncomir. By contrast, members of the tumor-suppressor miR
let-7 family are downregulated in many cancers and inhibit
tumor growth by targeting various oncogenes and main regu-
lators of mitogenic pathways, including c-myc, RAS and
HMGA2 [10]. miR-34 is another well-known tumor suppressor,
which is the effector of TP53 activation [11].
The role of miR-21 in ovarian cancer
miR-21 is a cancer-associated miR (onco-miR) that is
overexpressed in most human tumors, especially in highly
aggressive tumors. miR-21 promotes malignant growth and
progression by acting on multiple targets, including an inhi-
bition of PTEN [phosphatase and tensin homolog e an up-
stream negative regulator of mammalian target of rapamycin
(mTOR)], activation of nuclear factor (NF)-kB activity,
enhanced formation of reactive oxygen species (ROS),
inducing tumor angiogenesis and through it activation of the
AKT and ERK1/2 signaling pathways, thereby enhancing
hypoxia-inducible factor 1, alpha subunit (HIF-1a) andvascular endothelial growth factor (VEGF) expression,
reduction of the expression of potent human anti-inflammatory
molecules, such as interleukin(IL)-10, and transforming
growth factor(TGF)-b [12]. In ovarian cancer, the role of miR-
21 on biological behavior and function is uncertain, although
one study showed that downregulation of miR-21 by short
hairpin (sh)RNA could significantly increase the percentage of
cell apoptosis and necrosis compared with that in the control
group, and by transwell migration assay and scratch wound
assay, the ability of migration of OVCAR3 significantly
decreased in the group with downregulation of miR-21 [13].
The potential target gene of miR-21 in ovarian cancer might be
programmed cell death 4 (PDCD4), ribosomal protein (RPS)
7, non-structural maintenance of chromosome (SMC) con-
densin I complex, subunit G (NCAPG), tropomyosins (TPM1)
and PTEN [1]. In addition, by contrast, Nam et al found that
the majority of ovarian cancer samples (85%) showed upre-
gulation of miR-21 from their identification of 23 aberrantly
expressed miRs in at least 60% of ovarian cancer samples [14].
However, in a study by Iorio et al, upregulation of miR-21 was
only found in endometrioid carcinomas of the ovary [15].
Therefore, in a later study in 2011 [16], The Cancer Genome
Atlas (TCGA) provided the first comprehensive molecular
classification of a large cohort of high-grade serous ovarian
carcinomas by integrated analyses of multidimensional data,
including miR expression profiles, to identify molecular ab-
normalities that influence ovarian cancer pathophysiology,
affect outcome and constitute therapeutic targets [16], based
on worst outcome of the ovarian cancer, including Taiwan
[17,18]. However, in 2003, Yang et al used an integrated
genomic analyses to reveal a miR-regulatory network that
further defined a robust integrated mesenchymal subtype
associated with poor overall survival in 459 cases of serous
ovarian cancer from TCGA and 560 cases from independent
cohorts and identified eight key miRs, including miR-25, miR-
506, miR-29c, miR-182, miR-128, miR-101, miR-141 and miR-
200a, which were predicted to regulate 89% of the targets in
this network [19]. Furthermore, they used a nanoparticle de-
livery of miR-506 in orthotopic ovarian cancer mouse models
leading to E-cadherin induction and reducing tumor growth
[19]. Therefore, the role of miR-21 in ovarian cancer needs
further confirmation, but there is no doubt that miR can be
used in ovarian cancer, not only a diagnostic tool, but also as a
predictor for outcome [2,19].
CSCs control the development and progression of
different malignancies
Unlike the aberrant miR expression in somatic cells, which
can promote tumorigenesis, altered expression of miR in
germline cells may predispose to cancer development [2]. One
emerging hypothesis for cancer development appeared to be
the existence of CSCs (or also called tumor initiating cells or
tumor progenitor cells) that were believed to be fully
responsible for tumor formation and progression, and have the
ability of self-renewal [20]. Several signaling pathways and
molecules were designated to modulate CSCs, such as
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Bmi-1 [21]. CSCs in different cancers could be identified by
different methods, such as fluorescent-activated cell sorting
(FACS) by cell surface markers, efflux of Hoechst dye for
isolating side population cells, overexpression of enzyme
alcohol dehydrogenase or single colony selection. Ovarian
CSCs, identified by cell surface markers CD44 and CD117, or
CD133, were demonstrated to have tumorigenic potency,
stemness ability, chemoresistance and the ability to induce
distant metastasis in many previous studies [20]. The expres-
sion of CD133 defined a tumor initiating subpopulation of
human ovarian cancer in the NOD/SCID model [21]. More-
over, anti-CD133 targeted toxin used in an in vivo ovarian
cancer model could markedly reduce the progression of
intraperitoneal ovarian cancer despite the low percentage of
CD133 expression [22].
miRNAs can affect functions of CSCs
Several studies have recently confirmed that miRNAs also
play a vital role in affecting the function of CSCs. For brain
cancer, miR-34 was involved in the survival, apoptosis and
self-renewal of CSCs through its target gene, such as Wnt3,
MYC, Notch and Bcl-2. Restitution of miR-34 could inhibit
tumor sphere growth in vitro and tumor formation in vivo [23].
Moreover, restitution of miR-34 also inhibited the growth of
CSCs with surface markers of CD44þ/CD133þ. Likewise,
overexpression of miR-199-5p could decrease tumor devel-
opment of medulloblastoma through reducing CD133þ sub-
population cells and targeting HES-1, a transcription factor of
the Notch signaling pathway. In addition to confirming the
suppression of the properties of prostate CSCs, CD44, a cell
marker for prostate CSCs, was proven to be a direct and
relevant downstream target of miR-34a simultaneously. The
protein level of CD44 could be reduced in overexpression of
miR-34a. In breast CSCs, let-7 could also regulate the char-
acteristics of stem cells, including self-renewal andTable 1
List of dysregulated miRNAs related to functions of ovarian cancer stem cells.
miRNAs (miR) Up/Downregulation Poten
miR-15a, miR-16a Down BAZ2
miR-21 Up PDCD
miR-34a, miR-34b, miR-34c Down SIRT1
miR-98 Down HMG
miR-138 Down SOX4
miR-181a, miR-181b Up HOXA
miR-187 Dual roles Dab2
miR-377 Down REST
miR-let-7b, miR-let-7d, miR-let-7e, miR-let-7f Down c-Myc
BAZ2A ¼ bromodomain adjacent to zinc finger domain, 2A; Bcl-2 ¼ B cell lym
CDX2 ¼ caudal type homeobox 2; cJUN ¼ jun proto-oncogene; Dab2 ¼ Disabl
blastosis virus E26 oncogene homolog 1; GATS ¼ stromal antigen 3 opposite stran
hook 2; HOXA11 ¼ homeobox A11; IL-6 ¼ interleukin 6; KLF2 ¼ Kruppel-like fa
homolog B; MCL ¼ malyl-CoA lyase/b-methylmalyl-CoA lyase; MYC ¼ myelo
chromosome (SMC) condensin I complex, subunit G; NLK ¼ nemo-like kinase;
REST ¼ RE1-silencing transcription factor; RPS ¼ ribosomal proteins; SIR ¼ sirt
1X-linked; TPM ¼ tropomyosins; Wnt3 ¼ glycoproteins acting as ligands to proddifferentiation [24]. Overexpression of let-7 could inhibit
mammosphere formation, tumor formation, distant metastasis
in the NOD/SCID model and even reduce the proportion of
undifferentiated cells in vitro. However, recent studies suggest
that other miRs, in addition to let-7, might simultaneously play
a role in regulating breast CSCs because overexpression of let-
7 alone was not sufficient to completely block the function of
CSCs. More complete inhibition of self-renewal and mam-
mosphere formation in breast CSCs could be achieved when
let-7 was simultaneously introduced with miR-30 compared
with either one alone. This synergistic inhibition effect of let-7
and miR-30 on breast CSCs suggests that multiple miRNAs
might concertedly regulate the function of CSCs.
Association between miRNA-21 and CSCs
Strong associations between miR-21 and CSCs were
confirmed in different types of cancer. Overexpression of miR-
21 not only contributed to epithelialemesenchymal transition
by activation of mesenchymal cell markers (N-cadherin,
Vimentin, a-SMA) and inhibition of the epithelial cell marker,
E-cadherin, in the MCF-7 cell line but also increased sub-
population cells expressing surface markers (ALDH1þ,
CD44þ/CD24e/low) and the ability of sphere formation [25].
Epithelialemesenchymal transition reversed by antagonism of
miR-21 indicated the key role of miR-21 in regulating CSC-
associated features [26]. In hepatocellular carcinoma side
population CSCs, miR-21 was shown to be upregulated in
regulating the ability of invasion and migration [27].
Furthermore, miR-21 could maintain the chemoresistance of
these side population CSCs. Inhibition of miR-21 by temo-
zolomide, an alkylating agent, used as a chemotherapeutic
agent for treating glioblastoma, significantly enhanced
apoptosis of glioblastoma cells [28]. Finally, miR-21 was also
shown to play an important role in ovarian CSCs [29]. When
using the miRNA microarray to analyze the expression of
miRNAs in CD133þ spheroid-forming cells of the OVCAR3tial targets References
A, Bcl-2, CCND1, Wnt3, BMI-1, ETS1, c-JUN, MCL1 [14,27,28]
4, RPS7, NCAPG, TPM1, PTEN [29]
, MYC, NOTCH, Bcl-2, CCND1, Wnt3 [14,15,29,31e34]
A2, Lin28B, HIC2 [15]
, HIF-1a [35]
11, GATS6, NLK, CDX2, TBL1X, DPP6, KLF2 [29,33,36]
[37]
, SOD1 [31,38]
, KRAS, HMGA2, IL-6, LiN28B, HIC2 [14,15,29,34,39]
phoma 2; BMI-1 ¼ polycomb ring finger oncogene; CCND1 ¼ cyclin D1;
ed homolog-2; DPP6 ¼ dipeptidyl-peptidase 6; ETS1 ¼ v-ets avian erythro-
d; HIC2 ¼ hypermethylated in cancer 2; HMGA2 ¼ high mobility group AT-
ctor 2; KRAS ¼ Kirsten rat sarcoma viral oncogene homolog; Lin28B ¼ lin-28
cytomatosis oncogene homolog; NACAPG ¼ non-structural maintenance of
PDCD ¼ programmed cell death; PTEN ¼ phosphatase and tensin homolog;
ulin; SOD1 ¼ superoxide dismutase 1, soluble; TBL1X ¼ transducin (b)-like
uce cell responses playing a variety of important roles 3.
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therefore, it can be supposed that dysregulation of miR-21 may
play an important role in stem cell-like properties of ovarian
CSCs.
miRNA-21 and other miRs exert a broad regulatory role
on ovarian CSCs
A recent publication from the China Medical University in
Taichung, entitled “MicroRNA-21 promotes ovarian terato-
carcinoma by sustaining cancer stem/progenitor populations
in vitro”, by Chung et al, proved that miR-21 regulates cell
growth and sphere formation of the ovarian teratocarcinoma
cell line PA1 through CD133 CSCs when knockdown of miR-
21, the CD133þ subpopulation and sphere formation were
significantly educed [30]. Moreover, overexpression of miR-21
induced a marked increase in the CD133þ subpopulation as
well as sphere formation. These authors provided direct evi-
dence that miR-21 targeted CD133 to affect the function of the
ovarian teratocarcinoma cell line PA1. Actually, other miRs,
such as miR-34, miR-181 and let-7, were also shown to play
important roles in ovarian carcinogenesis and the function of
cancer stemness, or even directly affecting CSCs besides miR-
21 (Table 1) [14,15,27e29,31e39]. Dysregulation of these
miRs may be implicated in the development of ovarian cancer,
or even CSCs. These new findings improve our understanding
of ovarian cancer. Given that ovarian CSCs appeared to be
involved in tumorigenesis, distant metastasis and therapy
resistance, and that miRNAs exerted a broad regulatory role on
CSCs, miR-based therapies might add novel firepower in the
anticancer weapon store. In addition to developing miRs as an
anti-CSC therapy, miR expression profiling in CSCs or specific
subtypes of cancer might also have diagnostic and prognostic
value in the future.
Conclusion
The discovery of aberrant expression of miRs has defined
new pathways in ovarian tumorigenesis and progression,
because miR profiles presented either in tissues or biological
fluids, such as blood, can potentially be used for the purpose of
early detection or surveillance of cancers, and target therapy
with miR might be a promising area, which might not only
significantly decrease the toxicity of conventional therapy but
also enhance therapeutic effects, as mentioned previously
[40,41].
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